Status:

RECRUITING

Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study

Lead Sponsor:

SonoMotion

Collaborating Sponsors:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions:

Renal Calculi

Urinary Calculi

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This is a prospective, open-label, multi-center, single-arm (non-randomized) study to assess the safety and effectiveness of breaking stones in the upper urinary tract using the SonoMotion Break Wave ...

Eligibility Criteria

Inclusion

  • Individuals presenting with at least one kidney stone apparent on CT.
  • Stones must be within the upper urinary tract.
  • Stones are indicated for SWL treatment per the American Urology Association (AUA) 2016 guidelines.8
  • Stones must be measured under CT to be within the AUA 2016 SWL guidelines (i.e. ≤ 10 mm for lower pole stones and ≤ 20 mm for non-lower pole stones).

Exclusion

  • Acute untreated urinary tract infection or urosepsis.
  • Uncorrected bleeding disorders or coagulopathies.
  • Pregnancy.
  • Uncorrected obstruction distal to the stone.
  • Patients receiving anticoagulants and who are unable or not willing to cease the medication for the Break Wave procedure.
  • Stones that are not echogenically visible or cannot be positioned within the Break Wave therapy focus.
  • Individuals belonging to a vulnerable group (pregnant, mentally disabled, prisoner, etc.).
  • Patients unwilling to comply with the follow-up protocol, including post-procedure CT.
  • Individuals under 18 years of age.
  • Anatomic presentations preventing adequate positioning or delivery of the Break Wave pulse.
  • Calcified abdominal aortic aneurysms or calcified renal artery aneurysms.
  • Solitary kidney
  • Comorbidity risks which, in at the discretion of the physician, would make the patient a poor candidate for the Break Wave procedure, such as anatomical anomalies that may not be conducive to adequate stone fragment passage.

Key Trial Info

Start Date :

August 20 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 30 2027

Estimated Enrollment :

70 Patients enrolled

Trial Details

Trial ID

NCT03811171

Start Date

August 20 2019

End Date

March 30 2027

Last Update

July 29 2025

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

University of California San Diego Health

San Diego, California, United States, 92103

2

University of California, San Francisco

San Francisco, California, United States, 94143

3

University of Washington Medical Center

Seattle, Washington, United States, 98195

4

University of Alberta, Division of Urology

Edmonton, Alberta, Canada, T6G1Z1

Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study | DecenTrialz